Rheumatology Therapeutics Market
Rheumatology Therapeutics Market Size, Share & Trends Analysis Report by Drug Type (Disease-modifying Anti-rheumatic Drugs, Nonsteroidal Anti-inflammatory Drugs, Corticosteroids, Uric Acid Drugs and Others), by Disease Indication (Rheumatoid Arthritis, Osteoarthritis, Gout, Psoriatic Arthritis, and Ankylosing Spondylitis), by Category (Prescription and Over-the-Counter (OTC), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy and Online Pharmacy), Forecast Period (2023-2030) Update Available - Forecast 2024-2030
Rheumatology Therapeutics market is anticipated to grow at a CAGR of 3.2% during the forecast period (2023-2030). Therapeutic drugs are used to slow down the progression of certain autoimmune rheumatic diseases such as rheumatic arthritis (RA). The increasing prevalence of RA globally has bolstered the launch of novel therapeutic agents and favorable refurbishment policies for high-cost treatment products are some of the factors driving the market growth. According to the National Institute of Health (NIH), in May 2023, rheumatic arthritis is more prevalent in women compared to men, with a lifetime risk of rheumatic arthritis of 3.6% in women compared to 1.7% in men. RA risk also increases with age, with a peak incidence between age 65 to 80 years of age. Furthermore, the rise in the rate of launches of novel biologics drugs, increasing approvals and growing penetration of generic drugs extend profitable opportunities to the rheumatology therapeutics market. For instance, in June 2022, Amgen announced that FDA approved RIABNI™ (rituximab-arrx), a biosimilar to Rituxan®, in combination with methotrexate for adults with moderate to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies.
Segmental Outlook
The global rheumatology therapeutics market is segmented on the drug type, disease indication, category, and distribution channel. Based on the drug type, the market is sub-segmented into disease-modifying anti-rheumatic drugs, nonsteroidal anti-inflammatory drugs, corticosteroids, uric acid drugs and others. Based on the disease indication, the market is sub-segmented into rheumatoid arthritis, osteoarthritis, gout, psoriatic arthritis, and ankylosing spondylitis. Based on the category, the market is bifurcated into prescription and OTC. Furthermore, on the basis of distribution channel, the market is sub-segmented into hospital pharmacy, retail pharmacy and online pharmacy. Among the disease indication, the rheumatoid arthritis sub-segment is anticipated to hold a considerable share of the market owing to the development of novel technologies such as clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9-based genome editing, RNA interference, PROTACs (proteolysis-targeted chimeras), and artificial intelligence (AI)-based drug design enable the screening of therapies targeting.
The Disease-modifying Anti-rheumatic Drugs (DMARDs) Sub-Segment is Anticipated to Hold a Considerable Share of the Global Rheumatology Therapeutics Market
Among the drug type, the sub-segment is expected to hold a considerable share of the global rheumatology therapeutics market. The segmental growth is attributed to the increased utilization of DMARD coupled with the rising incidence of RA around the globe. For instance, according to the National Center for Biotechnology Information, in June 2022, the annual incidence of RA in the US and other Western nations of northern Europe is about 40 per 100,000 persons. Owing to a surge in awareness related to treatment options available for RA.
Regional Outlook
The global rheumatology therapeutics market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, the Asia-Pacific region is anticipated to hold a prominent share of the market, owing to the increasing prevalence of rheumatoid arthritis, increasing awareness about the disorder, and increasing prevalence combined with the adoption of advanced rheumatoid arthritis therapeutics is expected to drive market growth. The key market player includes Chugai Pharmaceutical Co., Ltd., Dr Reddy's Laboratories Ltd. LG Chem, Lupin Ltd, Taisho Pharmaceutical Holdings Co., Ltd., and others.
Global Rheumatology Therapeutics Market Growth, by Region 2023-2030
The North America Region is Expected to Grow at a Significant CAGR in the Global Rheumatology Therapeutics Market
Among all regions, the North America region is anticipated to grow at a considerable CAGR over the forecast period. The regional market growth is attributed to the growing awareness regarding the early diagnosis and treatment of rheumatology disease and the increasing use of DMARD’s for treating. Furthermore, the rise in launches of novel biologics drugs, increasing approvals and growing penetration of generic drugs extend profitable opportunities to the rheumatology therapeutics market players. For instance, in July 2023, Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd., announced that after 5 years of use in Europe and two years in Canada, HULIO® (adalimumab-fkjp) injectable, a biosimilar to Humira® (adalimumab), is now accessible to patients in the US.
Market Players Outlook
The major companies serving the global rheumatology therapeutics market include F. Hoffmann-La Roche Ltd., Johnson & Johnson Private Ltd., Merck & Co., Inc., Novartis AG, Pfizer Inc., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in January 2023, Gilead Sciences, Inc. and EVOQ Therapeutics, Inc. collaborated along with a licensing agreement to advance EVOQ’s proprietary technology for the treatment of rheumatoid arthritis (RA) and lupus. EVOQ’s NanoDisc technology is designed to enable lymph-targeted delivery of disease-specific antigens and has the potential to change the paradigm for the treatment of autoimmune diseases.
The Report Covers
- Market value data analysis of 2022 and forecast to 2030.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global rheumatology therapeutics market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
• Current Industry Analysis and Growth Potential Outlook
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Region
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Key Company Analysis
3.2. Merck & Co., Inc.
3.2.1. Overview
3.2.2. Financial Analysis
3.2.3. SWOT Analysis
3.2.4. Recent Developments
3.3. Novartis AG
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments
3.4. Pfizer Inc.
3.4.1. Overview
3.4.2. Financial Analysis
3.4.3. SWOT Analysis
3.4.4. Recent Developments
3.5. Key Strategy Analysis
4. Market Segmentation
4.1. Global Rheumatology Therapeutics Market by Drug Type
4.1.1. Disease-Modifying Anti-Rheumatic Drugs
4.1.2. Non-Steroidal Anti-Inflammatory Drugs
4.1.3. Corticosteroids
4.1.4. Uric Acid Drugs
4.1.5. Others
4.2. Global Rheumatology Therapeutics Market by Disease Indication
4.2.1. Rheumatoid Arthritis
4.2.2. Osteoarthritis
4.2.3. Gout
4.2.4. Psoriatic Arthritis
4.2.5. Ankylosing Spondylitis
4.3. Global Rheumatology Therapeutics Market by Category
4.3.1. Prescription
4.3.2. Over-the-Counter (OTC)
4.4. Global Rheumatology Therapeutics Market by Distribution Channel
4.4.1. Hospital Pharmacy
4.4.2. Retail Pharmacy
4.4.3. Online Pharmacy
5. Regional Analysis
5.1. North America
5.1.1. United States
5.1.2. Canada
5.2. Europe
5.2.1. UK
5.2.2. Germany
5.2.3. Italy
5.2.4. Spain
5.2.5. France
5.2.6. Rest of Europe
5.3. Asia-Pacific
5.3.1. China
5.3.2. India
5.3.3. Japan
5.3.4. South Korea
5.3.5. Rest of Asia-Pacific
5.4. Rest of the World
6. Company Profiles
6.1. AbbVie Inc.
6.2. Amgen Inc.
6.3. AstraZeneca plc
6.4. Aurinia Pharmaceuticals Inc.
6.5. Boehringer Ingelheim International GmbH
6.6. Bristol-Myers Squibb Co.
6.7. Eli Lilly
6.8. F. Hoffmann-La Roche Ltd.
6.9. Gilead Sciences, Inc.
6.10. Janssen Pharmaceuticals, Inc.
6.11. Johnson & Johnson Private Ltd.
6.12. Regeneron Pharmaceuticals Inc.
6.13. Sanofi, Genentech, Inc.
6.14. Takeda Pharmaceutical Company Ltd.
6.15. UCB S.A.
1. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2022-2030 ($ MILLION)
2. GLOBAL DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS FOR RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
3. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS FOR RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
4. GLOBAL CORTICOSTEROIDS FOR RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
5. GLOBAL URIC ACID DRUGS FOR RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
6. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DISEASE INDICATION, 2022-2030 ($ MILLION)
7. GLOBAL RHEUMATOID ARTHRITIS THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
8. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
9. GLOBAL GOUT THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
10. GLOBAL PSORIATIC ARTHRITIS THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
11. GLOBAL ANKYLOSING SPONDYLITIS THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
12. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY CATEGORY, 2022-2030 ($ MILLION)
13. GLOBAL RHEUMATOLOGY THERAPEUTICS BY PRESCRIPTION MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
14. GLOBAL RHEUMATOLOGY THERAPEUTICS BY OVER-THE-COUNTER (OTC) MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
15. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2022-2030 ($ MILLION)
16. GLOBAL RHEUMATOLOGY THERAPEUTICS IN HOSPITAL PHARMACY MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
17. GLOBAL RHEUMATOLOGY THERAPEUTICS IN RETAIL PHARMACY MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
18. GLOBAL RHEUMATOLOGY THERAPEUTICS IN ONLINE PHARMACY MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
19. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
20. NORTH AMERICAN RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
21. NORTH AMERICAN RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2022-2030 ($ MILLION)
22. NORTH AMERICAN RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DISEASE INDICATION, 2022-2030 ($ MILLION)
23. NORTH AMERICAN RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY CATEGORY, 2022-2030 ($ MILLION)
24. NORTH AMERICAN RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2022-2030 ($ MILLION)
25. EUROPEAN RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
26. EUROPEAN RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2022-2030 ($ MILLION)
27. EUROPEAN RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DISEASE INDICATION, 2022-2030 ($ MILLION)
28. EUROPEAN RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY CATEGORY, 2022-2030 ($ MILLION)
29. EUROPEAN RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2022-2030 ($ MILLION)
30. ASIA- PACIFIC RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
31. ASIA- PACIFIC RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2022-2030 ($ MILLION)
32. ASIA- PACIFIC RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DISEASE INDICATION, 2022-2030 ($ MILLION)
33. ASIA- PACIFIC RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY CATEGORY, 2022-2030 ($ MILLION)
34. ASIA- PACIFIC RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2022-2030 ($ MILLION)
35. REST OF THE WORLD RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
36. REST OF THE WORLD RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2022-2030 ($ MILLION)
37. REST OF THE WORLD RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DISEASE INDICATION, 2022-2030 ($ MILLION)
38. REST OF THE WORLD RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY CATEGORY, 2022-2030 ($ MILLION)
39. REST OF THE WORLD RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2022-2030 ($ MILLION)
1. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2022 VS 2030 (%)
2. GLOBAL DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS FOR RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
3. GLOBAL NONSTEROIDAL ANTI-INFLAMMATORY DRUGS FOR RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
4. GLOBAL CORTICOSTEROIDS FOR RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
5. GLOBAL URIC ACID DRUGS FOR RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
6. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DISEASE INDICATION, 2022 VS 2030 (%)
7. GLOBAL RHEUMATOID ARTHRITIS THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
8. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
9. GLOBAL GOUT THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
10. GLOBAL PSORIATIC ARTHRITIS THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
11. GLOBAL ANKYLOSING SPONDYLITIS THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
12. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY CATEGORY, 2022 VS 2030 (%)
13. GLOBAL RHEUMATOLOGY THERAPEUTICS BY PRESCRIPTION MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
14. GLOBAL RHEUMATOLOGY THERAPEUTICS BY OVER-THE-COUNTER (OTC) MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
15. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2022 VS 2030 (%)
16. GLOBAL RHEUMATOLOGY THERAPEUTICS IN HOSPITAL PHARMACY MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
17. GLOBAL RHEUMATOLOGY THERAPEUTICS IN RETAIL PHARMACY MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
18. GLOBAL RHEUMATOLOGY THERAPEUTICS IN ONLINE PHARMACY MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
19. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
20. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SHARE BY REGION, 2022 VS 2030 (%)
21. US RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2022-2030 ($ MILLION)
22. CANADA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2022-2030 ($ MILLION)
23. UK RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2022-2030 ($ MILLION)
24. FRANCE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2022-2030 ($ MILLION)
25. GERMANY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2022-2030 ($ MILLION)
26. ITALY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2022-2030 ($ MILLION)
27. SPAIN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2022-2030 ($ MILLION)
28. REST OF EUROPE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2022-2030 ($ MILLION)
29. INDIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2022-2030 ($ MILLION)
30. CHINA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2022-2030 ($ MILLION)
31. JAPAN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2022-2030 ($ MILLION)
32. SOUTH KOREA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2022-2030 ($ MILLION)
33. REST OF ASIA-PACIFIC RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2022-2030 ($ MILLION)
34. REST OF THE WORLD RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2022-2030 ($ MILLION)
